BIOCARTIS AND A*STAR’S ETPL INITIATE DEVELOPMENT OF BREAST CANCER ASSAY TO GUIDE THERAPY SELECTION
Singapore / Mechelen (Belgium)- 10 July 2017 - Biocartis Group NV (‘Biocartis’ or the ‘Company’)- an innovative molecular diagnostics company (Euronext Brussels: BCART)- today announced that it has extended its partnership with ETPL (the commercialization arm of A*STAR- Singapore’s Agency for Science- Technology and Research1) with a new five-year strategic partnership- focused on the development of molecular diagnostic assays for Biocartis’ Idylla™ platform- a fully automated sample-to-result- real-time PCR (Polymerase Chain Reaction) system that offers accurate- highly reliable molecular information from virtually any biological sample. The first assay selected for development under the partnership is a fully automated solid biopsy assay- aimed at supporting optimal therapy selection decisions for breast cancer patients.
SPEECH BY MINISTER FOR HEALTH, MR GAN KIM YONG, AT THE A*STAR SCHOLARSHIP AWARD CEREMONY ON 10 JULY 2017, 3PM, LEVEL 2 AUDITORIUM, MATRIX, BIOPOLIS
R&D AND INVESTMENT IN SINGAPORE TALENT – KEY STRATEGIES FOR SINGAPORE’S FUTURE
R&D is a key strategy for Singapore’s future in building a knowledge-driven economy. Last year, the government announced the S$19 billion Research, Innovation and Enterprise 2020 (RIE2020) plan to support research, innovation and enterprise activities for the next five years. We are focusing our investments on key areas where there are national needs, economic opportunities as well as areas in which we have developed capabilities. Advanced Manufacturing and Engineering, Health and Biomedical Sciences, Urban Solutions and Sustainability, and Services and Digital Economy are the four domains that have been prioritised under RIE2020.
